Abstract: Taxanes are highly active chemotherapeutic agents in the treatment of early-stage and metastatic breast cancer. Novel formulationshavebeendevelopedtoimproveefficacyanddecreasetoxicityassociatedwiththesecytotoxicagents.nab-paclitaxel is a solvent free, albumin-bound 130-nanometer particle formulation of paclitaxel (Abraxane ® ,AbraxisBioscience),whichwasdeveloped to avoid toxicities of the Cremophor vehicle used in solvent-based paclitaxel. In a phase III clinical trial, nab-paclitaxel demonstrated higher response rates, better safety and side-effect profile compared to conventional paclitaxel, and improved survival in patients receivingitassecondlinetherapy.Higherdosescanbeadministeredoverashorterinfusiontimewithouttheneedforspecialinfusionsetsorpre-medications.ItisnowapprovedintheUSfortreatmentofbreastcancerafterfailureofcombinationchemotherapy formetastaticdiseaseorrelapsewithin6monthsofadjuvanttherapy,wherepriortherapyincludedananthracycline.Recently,several phase II studies have suggested a role for nab-paclitaxelasasingleagentandincombinationwithotheragentsforfirst-linetreatment of metastatic breast cancer.
Introduction
Taxanes (eg, paclitaxel, docetaxel) and anthracyclines (eg, doxorubicin, epirubicin) remain among the most activeandwidelyusedchemotherapyagentsinbreast cancer, both in adjuvant and metastatic settings. [1] [2] [3] A recent meta-analyses of 13 randomized clinical trialsshowedasignificantimprovementofdisease-free andoverallsurvival(OS)ratesinhigh-riskearlystage breastcancerwith chemotherapyregimensincorporating combination of taxanes and anthracyclines. 4 However, approximately 25%-30% of early stage breastcancerswillrecur.Thereisanimperativeneed for agents that not only overcome resistance but also have a favorable toxicity profile.The solvents used for dissolving hydrophobic molecules, paclitaxel and docetaxelareknowntobeassociatedwithsignificant riskofhypersensitivityreactionsandneuropathyand also impair drug delivery to the tumor, limiting their clinical effectiveness.
5,6
With the advent of nanotechnology, a novel formulation of solvent free 130-nanometer albuminbound paclitaxel (nab-paclitaxel, Abraxane This article provides a review of pharmacology, safety and efficacy profile of nab-paclitaxel, and evaluatesitsbenefitintreatmentofbreastcancer.
Side-Effects and Drawbacks of Solvent-Based Taxanes
Taxanes bind to the interior surface of β-microtubule chain and enhance tubulin polymerization, thereby stabilizing microtubules. This inhibits mitosis, motility andintracellulartransportwithin(cancer)cells,leadingtoapoptoticcelldeath.TaxanesalsoblockantiapoptoticeffectsofBCL-2genefamily,induceTP53 gene activation with resultant mitotic arrest leading to cell death. 7 Paclitaxelwasfirstapprovedin1992forclinical use. It is a naturally occurring diterpinoid product extractedfrombarkofpacificyew.Docetaxel,another taxane, which was approved by FDA for clinical use in 2004, is a semi-synthetic esterified product of 10-deacetyl baccatin III extracted from needles ofEuropeanyew.Bothpaclitaxelanddocetaxelare highlyhydrophobic.CremaphorEL(CrEL),anonionic surfactant poly-oxy-ethylated castor oil mixed 1:1withdehydratedethanolwasrecognizedtobethe most feasible option to solubilize paclitaxel for intravenousadministration.Likewise,thesolventusedfor Docetaxel is another poly-oxy-ethylated surfactant, polysorbate-80. 6 Being biologically and pharmacologically active, these solvents are associated with several major side effects such as hypersensitivity reactions and neuropathies. They also impair tumor penetration, limiting the clinical effectiveness of solvent-based taxanes. 5, 6 CrEL-paclitaxel formulation needs special infusion set to minimize exposure to di(2-ethylhexyl)phthalate (DHEP), which may be leached from standard polyvinyl chloride sets. Prolonged infusion times and premedications with corticosteroids and antihistamine agents are required toreducehypersensitivityreactions. However,minor reactions still occur in about 40% of all patients receiving solvent-based taxanes and nearly 3% develop potentially life-threatening reactions. 6 CrEL is also shown to cause neutropenia and prolonged peripheral neuropathy related to axonal degeneration.Fluidretention,atoxicitycommonlyseenwith docetaxel has been attributed in part due to alteration ofmembranefluiditybypolysorbate-80. 6, 8 Formation of large polar micelles of CrEL-paclitaxel in the plasma compartment can cause entrapment of the drug leading to non-linear pharmacokinetics. 5 This alters the pharmaco-dymanic characteristics of the solubilized drug resulting in a substantial increase in systemic exposure with concomitantly reduced systemicclearanceplacingpatientsatriskforsevere systemic toxicities. This drug entrapment phenomenonwhichdecreasesthedurationofdrugexposure partlyexplainswhytheattemptstoimproveefficacy ofCrEL-paclitaxelbyutilizingdoseshigherthanthe standard-of-caredose(175mg/m 2 over 3 hours every 3weeks)havebeenunsuccessful. 9 Morefrequentdosing(suchasweeklyadministration)whichmaylead to increased duration of exposure, has demonstrated improvedefficacyinbothadjuvant/ neoadjuvantand metastatic settings.
To address these limitations of solvent-based taxanes and to improve their therapeutic index, various solvent-free formulations and delivery systems such as liposomal encapsulated paclitaxel, paclitaxel vitamin E emulsion and polymer microsphere formulationofpaclitaxelwereinvestigatedbutwithlimited success. 6, 8 First successful attempt to formulate a solvent-free taxane has been the development of nab-paclitaxel. The nano-particle protein platform utilizes the natural properties of albumin to increase drug delivery to the tumor and eliminates the need for solvents.
Nanomedicine and nab-Technology
Nanomedicine is the medical application of molecular nab-technology,anewareaofsciencethatinvolves workingwithsmallscalematerialsanddevicesthat are at the nanometer level (10
of a meter).A few examples of the development by this discipline include liposomes, dendrimers, super paramagnetic nanoparticles and polymer-based platforms. 11 Albumin has a numberoffeaturesthatmakeitanidealdrugdelivery system. It is a natural carrier of endogenous hydrophobic molecules such as vitamins, hormones and other water-insolubleplasmasubstancesthatareboundin a reversible non-covalent manner. Albumin plays an important role in endothelial transcytosis of proteinbound and unbound plasma constituents mainly by bindingtoacell-surface60kDaglycoproteinrecep-tor (gp60) on the endothelial cell membrane. This leadstoactivationofcaveolin-1,amajorcomponent of membrane vesicles, resulting in receptor mediated internalization of the albumin-drug complex into caveolae (small invaginations of plasma membrane). Subsequently, caveolae transports the albumin-drug conjugate to the extracellular space, including the tumor interstitium. SPARC (secreted protein, acidic and rich in cysteine),whichisbelievedtobeselectively secreted by the tumors, binds to albumin-drug complexwiththeresultantreleaseofthedruginthe vicinity of tumor cells.
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Preclinical and Clinical Evaluation of nab-Paclitaxel
Comparative intratumoral and antitumoral activity of nab-paclitaxel has been demonstrated to be greater thanCrEL-paclitaxelanddocetaxelin multipletumor types using preclinical models. 14 In a panel of HCC cell lines studied, nab-paclitaxelshowedaneffective IC 50 dose at 15-fold lower than paclitaxel or docetaxel alone, and ∼450-foldlesscomparedto doxorubicin.SPARC,atypeofcaveolin-1hasasequence homologywithgp60,leadstoitsbindingtoalbumin. It is over expressed in several tumor types including breast cancer. This interaction between SPARC and albumin has been suggested to be the reason for enhanceduptakeandintra-tumoralaccumulation,and also a possible role for SPARC as a bio-marker for nab-paclitaxel effectiveness.
12 These data provided the preclinical evidence to advance the drug to clinical studies. A randomized cross over study comparing the pharmacokinetics of nab-paclitaxel and CrEL-paclitaxel was reported by Gardner et al. 17 Seventeen patients withlocallyadvancedormetastaticsolidtumorsthat were likely to be responsive to taxanes were randomized to receive nab-paclitaxel (260 mg/m 2 as a 30-minute infusion) or CrEL-paclitaxel (175 mg/m 2 as a 3 hour infusion). Patients crossed over to the alternate treatment after 1st cycle. Thereafter, patients receivedtreatmentswith260mg/m 2 of nab-paclitaxel every3weeks.Pharmacokineticstudieswerecarried outforthefirstcycleofCrEL-paclitaxelandthefirst two cycles of nab-paclitaxel. The total drug exposure was comparable between the two formulations and the mean fraction of unbound paclitaxel was significantlyhigherwithnab-paclitaxel compared to CrEL-paclitaxel (0.063 ± 0.021 vs. 0.024 ± 0.009; P , 0.001). This study purports that systemic exposure to unbound paclitaxel would lead to increased tumoral uptake thereby resulting in an augmented anti-tumorefficacycomparedtoCrEL-paclitaxel.
Phase 1 and Pharmacokinetic Studies
In a phase 1 study of three different schedules of nab-paclitaxel in combination with carboplatin, 18 41 heavily pretreated patients with advanced solid tumors received nab-paclitaxelandcarboplatinAUC of 6 on day 1. Group A received nab-paclitaxel at dosesrangingfrom220to340mg/m 2 on day 1 every 21 days; group B received nab-paclitaxel at 100 or 125mg/m 2 ondays1,8,and15every28days;and group C received nab-paclitaxel125or150mg/m 2 on days1and8every21days.MTDofnab-paclitaxel in combination with carboplatin was 300, 100, and 125mg/m 2 ingroupsA,B,andC,respectivelywith myelosuppressionwastheprimarydoselimitingtoxicity in all the groups.
In a recent phase 1 study reported by Chien et al, 19 vascular-primingchemosensitizationwith2-daypulse of high dose lapatinib followed by weekly infusion of 100 mg/m 2 nab-paclitaxel treatment was investigatedin25patientswithadvancedsolidtumors.72% of these patients were previously taxane-refractory. Maximumtolerateddoseoflapatinibwasdefinedas 5250mg/dayindivideddoses.Thedose-limitingtoxicitiesweregrade3vomitingandgrade4 neutropenia. 65% of evaluable patients had a partial or stable response on this therapy.
Phase II Studies
Based on the results of phase 1 study, 15 Ibrahim et al investigated nab-paclitaxel in a multicenter phase II study to evaluate safety and antitumor activity in patients withMBC. 20 63womenwithconfirmedandmeasur-ableMBCreceived300mg/m 2 of nab-paclitaxel over 30 minutes every 3 weeks. 48 patients had received priorchemotherapy;39patientshadreceivednoprior treatment for metastatic disease. Median number of treatmentswas6cycles.Overallresponserate(ORR), which was the primary end point of the study, was 48%forallpatientsand64%forthosereceivingnab-paclitaxelasfirstlinetreatment.Mediantimetoprogression(TTP)was26.6weeksandmedianOSwas 63.6weeks.Noseverehypersensitivityreactionswere reported despite lack of premedication. Toxicities noted were typical of paclitaxel and included grade 4neutropenia(24%)andgrade3sensoryneuropathy (11%)andgrade4febrileneutropenia(5% 
event).
Of 29 patients, 34% received peg-filgrastim during nab-paclitaxeltherapyand31%hada nab-paclitaxel treatment delay, mainly due to hematologic toxicity. Based on Kaplan-Meier probability estimates, the percentage of patients having #1 grade neuropathy at the end of treatment, 2, and 8 months after treatment were 59, 79, and 97%.The authors concluded thatadministeringadjuvantdose-denseACfollowed by260mg/m2dose-densenab-paclitaxelwasfeasible inwomenwithearly-stageBC,withmanageableAEs. Mostpatientshad#1gradeneuropathy2monthsafter treatment completion.
nab-paclitaxel administered sequentially with anthracyclinehasalsobeenevaluatedinaneoadjuvant setting for locally advanced breast cancer (LABC) in a phase II study by Robidoux et al 26 66 patients withLABCbutwithoutpriortreatmentandregardlessofhormonereceptororHER2statusweretreated with nab-paclitaxel weekly for 12 weeks followed by 5-fluorouracil, epirubicin and cyclophosphamide (FEC) every 3 weeks for 4 cycles. Trastuzumab was allowed in HER2-positive (HER2+) patients. Sixty-threepatientscompleted4cyclesofalbumin-bound paclitaxel following which 58 completed 4 cycles FEC. 17 of 19 HER2+ patients received trastuzumab. Pathologic complete response (pCR), the primary objective of the study, was 29% (19 of 65).FortheHER2+subset,thepCRwas58%(11of 19).Bothnab-paclitaxelandFECwerewell tolerated. Themostsignificanttoxicitiesweregrade2/3neurop-athy(16%)withnab-paclitaxelandgrade3/4febrile neutropenia(7%)withFEC.
These studies suggest that nab-paclitaxel alone or in combination with other therapeutic agents has (Table 3) .
Phase III Studies
Based on the favorable phase I and phase II data, nab-paclitaxel's antitumor efficacy and safety was compared to CrEL-paclitaxel in a pivotal, multi-national randomized phase III trial conducted at70sitesin5countries. 27 Ofthe460womenwith MBCenrolledinthestudy,454wererandomizedto 3-weekly cycles of either nab-paclitaxel at a dose of 260 mg/m 2 intravenously over 30 minutes without premeditation (n =229)orCrEL-paclitaxelata doseof175mg/m 2 intravenouslyover3hourswith corticosteroid and antihistamine premedications (n = 225). The large majority of patients had more thanthreemetastaticlesions(76%),visceraldisease (79%), prior chemotherapy (86%), and progression after first-line therapy for metastatic disease (59%). SimilarresultswerereportedfromaphaseIIItrial comparing nab-paclitaxelwithCrEL-paclitaxelin210 ChinesepatientswithMBC. 28 Patientswereequally randomized to receive either nab-paclitaxel260mg/ m 2 over 30 min every 3 weeks with no premedication or CrEL-paclitaxel 175 mg/m 2 over 3 hours every 3 weeks with standard premedication. ORR was52%inthenab-paclitaxelgroupand27%inthe CrEL-paclitaxelgroup(P ,0.001).MedianTTP(7.6 months vs. 5.7 months; p = 0.03) and median PFS (7.6monthsvs.6.2months;p=0.118)"to"Median TTP(7.6monthsvs.5.7months;p=0.03)wassignificantly higher in the nab-paclitaxel group. The most common toxicities reported were alopecia (78%), peripheralneuropathy(75%,7%grade3)andneutropenia(65%)andweresimilarbetweenthe2groups.
These trials corroborate the results of the preclinical and phase I/II clinical trials that the use of the nab-paclitaxel formulation could result in clinically relevant improvements in the toxicity and the efficacy of paclitaxel. In particular the incidence of any grade3and4neutropeniawassignificantlyreduced in patients receiving nab-paclitaxel compared with those receiving paclitaxel, despite an increase in the dose of paclitaxel. Grade 3 sensory neuropathy washigherwithnab-paclitaxelbutmanageablewith quick improvement to lower grades. Interestingly, nab-paclitaxel prolonged survival in patients with metastaticbreastcancerthatwasresistanttoanthracyclineaftertreatmentintheadjuvantormetastatic setting.
Therapeutic applicability of nab-paclitaxelisnow being tested in variety of tumor types, including non small cell lung cancer, pancreatic cancer and melanoma at different stages of disease, as a single agent andincombinationwithothercytotoxicchemotherapyand/orbiologicagents.ThecurrentlyactivePhase IIIclinicaltrialsinbreastcancerwithnab-paclitaxel are listed in Table 4 .
Tolerability and Economic Analysis of nab-paclitaxel
The overall tolerability of nab-paclitaxel260mg/m 2 wasreportedtobesimilartothatofCrEL-paclitaxel 175mg/m 2 in the phase III trial. 27 No differences in qualityoflifethroughoutthestudywerenotedbetween thetwotreatmentgroupsdespitehigherdose-intensity of paclitaxel in the nab-paclitaxel group (85.13 vs. 57.02 mg/m 2 /week). The most commonly reported toxicities/adverse events during the study were as expected for paclitaxel and included alopecia (90% vs.94%),sensoryneuropathy(71%vs.56%),fatigue (47%vs.38%),neutropenia(34%vs.49%),arthralgia (35%vs.33%),myalgia(28%vs.32%),nausea(30% vs. 21%), infections (24% vs. 20%), and diarrhea (26%vs.15%)for nab-paclitaxelvs.CrEL-paclitaxel groupsrespectively.Fewereventsofneutropeniaand skin flushing were reported among nab-paclitaxel recipients than CrEL-paclitaxel recipients, where as sensory neuropathy and gastrointestinal symptoms were higher with nab-paclitaxel but this resolved more rapidly after treatment withdrawal.There was no report of grade 4 sensory neuropathy. The side effects are summarized in Table5 Although nab-paclitaxel is more expensive than solventbasedtaxanes,itsbettertoxicityprofile,faster infusiontimeandpackofneedforpremedicationsare significant cost savings compared to solvent based product.Dranitsarisetal 30 has recently published an economic analysis of the phase II randomized study comparing nab-paclitaxel weekly or every 3 weeks tostandarddocetaxelasfirstlinetherapyinpatients withMBC.Clinicalandresourceusedatawascaptured from the trial's database and an economic analysis was performed from the perspective of United Kingdom National Health Service (UK NHS). The costs of chemotherapy, drug delivery, monitoring, supportive care drugs and hospitalization due to toxicitywasincluded.Aunivariateandmultivariate regression analysis was performed to compare the total cost of therapy in patients randomized to each of the four arms of the study. When all cost componentswerecombinedfortheentirestudypopulation (n = 300), patients in nab-paclitaxel100mg/m 2 once 
Future Perspectives Biomarker studies
SPARCisknowntobeoverexpressedinseveraltumor types including breast cancer and may be associated with a poor prognosis. In preclinical breast cancer models 12 and recently in a retrospective analysis of a clinical study 31 of nab-paclitaxelinheadandneck cancer, SPARC expression and its interaction with albumin has been suggested to be the reason for enhanceduptakeandintratumoralaccumulationindicatingapossibleroleforSPARCasabio-markerfor nab-paclitaxel effectiveness. To corroborate these findings, a current phase III study (NCT00785291) in MBC by Cancer and Leukemia Group B/North CentralCancerTreatmentGroup(CALGB/NCCTG) isevaluatingtheserumandtumorbiomarkers(caveolin-1andSPARC)alongwithcirculatingtumorcells toassesstheirpossibleroleaspredictivemarkersof responseinMBC.
nab-paclitaxel in lung cancer
Besides breast cancer, nab-paclitaxel is being investigatedinavarietyofothersolidtumors.Resultsfrom Phase II study 32 in advanced non small cell lung cancer (NSCLC) has demonstrated that nab-paclitaxel at a dose of 260 mg/m 2 every 3 weeks is well tolerated;showedaresponserateof16%,anddisease control rate of 49% with a median time to progressionof6monthsandmediansurvivalof11months. In another phase II study 33 
nab-paclitaxel as a radiosensitizer
Preclinical studies in mice bearing syngeneic ovarian or breast cancer have shown that nab-paclitaxel improved radiotherapy in a supra-additive manner suggesting that combining nab-paclitaxelwithradiotherapywouldimprovetheoutcomeoftaxane-based chemoradiotherapy.
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Other nab-compounds in pipeline
The nab technology has potential for improving drug deliveryandenhancingtherapeuticratioofotherwaterinsolubledrugs.Threesuchdrugswith nab-application are currently in the clinical studies. nab-docetaxel (ABI-008),asolvent-freenanometersizedformofdocetaxelisbeingstudiedinphaseI/IItrialforpatientswith hormonerefractoryprostatecancer(NCT00477529). 36 Rapamycin is an inhibitor of mammalian target of rapamycin (mTOR), a kinase member of signaling pathway that promotes tumor growth. nab-rapamycin (ABI-009) currently being studied in a phase I trial (NCT00635284) 36 in various non-hematological malignancies is purported to overcome the poor aqueous solubility and poor chemical stability,whichhadlimited rapamycin's development as an anticancer agent. 17-AAG(17-N-allylamino-17-demethoxygeldanamycin; tanespimycin) is an antineoplastic antibiotic derivative ofgeldanamycinandisaheatshockprotein90(hsp90) inhibitor. nab-17-AAG(ABI-010)incombinationwith nab-paclitaxeladministeredweeklywillbestudiedin a currently pending phase I trial (NCT00820768) for various non-hematological malignancies.
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Concluding remarks
Contemporary cancer therapeutics, including treatment of breast cancer, is centered on the concept of personalized medicine. The emphasis is to tailor therapytoeachpatientbasedonspecifictumorphenotype and genomic analysis. Treatment decisions are based not only on predictive and prognostic factors, but also onsafetyprofile,impactonqualityoflifeandpatient preference. In the past decade, several studies have demonstrated that taxanes are an essential component intreatmentofbreastcancerbothinadjuvantandmetastaticsettings.Usingnab-technology platform, nabpaclitaxelwasdevelopedtoovercomethelimitations of solvents used in conventional solvent-based taxanes. Clinical data show that nab-paclitaxel has a better safetyandsideeffectprofilewithanimprovedefficacy compared to solvent-based taxanes. Higher doses can be administered over a shorter infusion time without the need for special infusion sets or premedications. ThephaseIIandPhaseIIIstudiesshowedsignificant improvement in tumor response rate and progression freeintervalswithnab -paclitaxel but did not demonstrate survival benefit except when used in secondline or greater therapy where the benefit was about 9.7weeks.Theseencouragingresultshaveprompted initiationofseveralclinicaltrials,whicharecurrently underwayevaluatingtheroleofnab-paclitaxel as a singleagentorincombinationwithcytotoxicand/orbiologic agents in breast cancer and other solid tumors.
